iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical enterprise... iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical enterprise headquartered in Singapore since its inception in 2004, focuses on the research, development, manufacturing, and commercialization of therapeutic solutions. The company targets acute and breakthrough pain, alongside various other health conditions, serving markets in Singapore, the United States, China, and Australia through its Specialty Pharmaceutical and Nutraceutical divisions. Its commercial offerings include Wafesil and Silcap, both indicated for male erectile dysfunction. Additionally, the company markets Xativa, a sublingual cannabidiol wafer, and Hypera, a sublingual tetrahydrocannabinol wafer, which address chronic pain, anxiety, and insomnia. iX Biopharma boasts an extensive product pipeline. Wafermine, a racemic ketamine sublingual wafer designed for complex regional pain syndrome and psychiatric conditions like depression, has successfully advanced through Phase 2 clinical trials. Other investigational candidates that have completed Phase 1 trials include iXB 120 for acute agitation, IXB-214 for complex regional pain syndrome, and IXB-314 for treatment-resistant depression. Furthermore, BnoX is currently undergoing Phase 1 evaluation for moderate to severe pain. In earlier development stages, iXB 401, a sublingual semaglutide wafer, is in pre-clinical development for Type 2 Diabetes and obesity. The pipeline also encompasses SL-NAD+, a sublingual NAD+ wafer engineered to boost the body's NAD+ levels, energy, and alertness; a distinct NAD+ product targeting sarcopenia; iXB 321, an influenza vaccine; iXB 322, a novel low-dose interferon sublingual wafer for respiratory viral prophylaxis; and LumeniX, a sublingual glutathione wafer offering benefits for skin brightening and immunity.
